Loading the records…
Loading the records…
The Women's Heart Health Expansion Act reauthorizes the WISEWOMAN program with $250M authorized over FY2027-2031 for cardiovascular screenings. The bill is in committee with bipartisan support, but actual funding requires separate appropriations. Diagnostic lab companies $DGX and $LH may see modest incremental revenue from grant-funded screening volume.
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
The bill's low authorization amount and early legislative stage mean no immediate market catalyst. Diagnostic lab stocks ($DGX, $LH) are structurally positioned to capture incremental screening volume if appropriations follow, but the impact is negligible relative to their overall revenue. No real market data is available to cite price movements.
The Women's Heart Health Expansion Act of 2026 (S.3944) was introduced on February 26, 2026 by Sen. Alsobrooks (D-MD) with original cosponsor Sen. Britt (R-AL). Hearings were held on March 19, 2026 in the Senate HELP Committee. The bill amends the Public Health Service Act to reauthorize the WISEWOMAN program, which provides supplemental grants for preventive health services including blood pressure, cholesterol, and obesity screenings for women. It authorizes $250 million for fiscal years 2027 through 2031.
The money trail: This is an authorization bill, not an appropriation. It sets a spending ceiling of $250M over five years, but actual funding depends on annual appropriations bills. The grants flow to entities already receiving breast and cervical cancer screening grants (section 1501) and other health care entities designated by the Secretary. These entities will purchase laboratory testing services from companies like Quest Diagnostics ($DGX) and LabCorp ($LH) to perform the screenings. The annual authorization of $50M is small relative to the $10B+ revenues of these diagnostic companies, so revenue impact is minimal.
Structural winners: Diagnostic lab companies are the most direct beneficiaries as they provide the blood work and lipid panels required. Hospital systems ($HCA) and health insurers ($UNH) may see downstream benefits from earlier detection, but the link is weaker. No pure-play women's health screening companies are publicly traded at scale.
Timeline: The bill is at hearing/markup stage. It must pass the Senate HELP Committee, then the full Senate, then the House (no companion bill yet), and be signed by The President. Given bipartisan sponsorship and the program's existing authorization, passage is plausible but not imminent. Actual market impact will only materialize after appropriations are passed, likely in FY2027.
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Authorizes supplemental grants for preventive health services including blood pressure, cholesterol, and obesity screenings under the WISEWOMAN program.
Who must act
Recipients of grants under section 1501 of the Public Health Service Act (state and local health departments, community health centers) that apply for supplemental grants.
What happens
Increased demand for laboratory diagnostic testing services (blood panels, lipid profiles) from grant-funded screening projects.
Stock impact
Quest Diagnostics provides clinical lab testing services; incremental revenue from increased screening volume under the program, estimated at $5M-$20M annually (less than 0.2% of total revenue).
What the bill does
Same as above: authorizes grants for preventive health services including screenings.
Who must act
Same grant recipients as above.
What happens
Increased demand for laboratory diagnostic testing services from grant-funded screening projects.
Stock impact
LabCorp provides clinical lab testing services; incremental revenue from increased screening volume under the program, estimated at $5M-$20M annually (less than 0.2% of total revenue).
Matched on shared policy language across AI analyses, with ticker & timing weight
Executive orders & memoranda affecting the same sectors or companies
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Free — no credit card
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →